Skip to main content
Clinical Trials/NCT04906772
NCT04906772
Completed
Phase 4

Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Upper Gastro-intestinal Endoscopy in Hepatic Patients (a Comparative Randomized Study)

Tamer Nabil Abdelrahman1 site in 1 country70 target enrollmentFebruary 3, 2021

Overview

Phase
Phase 4
Intervention
Dexmedetomidine
Conditions
Anesthesia; Reaction
Sponsor
Tamer Nabil Abdelrahman
Enrollment
70
Locations
1
Primary Endpoint
induction time
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

We aim to compare the response to ketamine/dexmedetomidine and ketamine/propofol combinations used in hepatic patients with child-Pugh classification (class A), and early (class B) undergoing UGIE.

Detailed Description

70 Patients will be randomly allocated into two groups; Group (KD): Ketamine/dexmedetomidine (35 patients), will receive IV ketamine 0.25mg/kg and dexmedetomidine1µg/kg over 10 min as loading followed by dexmedetomidine infusion with a rate of 0.5µg/kg/hr and Group (KP): ketamine/propofol (35 patients) will receive IV ketamine 0.25 mg/kg loading and propofol 1 mg/kg over 10 min followed by propofol infusion with a rate of 0.5 mg/kg/hr as a control group.

Registry
clinicaltrials.gov
Start Date
February 3, 2021
End Date
September 30, 2021
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Tamer Nabil Abdelrahman
Responsible Party
Sponsor Investigator
Principal Investigator

Tamer Nabil Abdelrahman

lecturer of anaesthesia, intensive care and pain management

Ain Shams University

Eligibility Criteria

Inclusion Criteria

  • hepatic patients with child-Pugh classification (class A), and (class B)
  • American Society of Anesthesiologists physical status II, III
  • aged 18 to 60 years
  • scheduled for elective Upper gastro-intestinal endoscopy.

Exclusion Criteria

  • emergency gastro-intestinal endoscopy.
  • patients with severe hepatic disorder (Child C) ,
  • chronic neuro-psychiatric disorder,
  • history of neuro-psychiatric drug intake,
  • severe cardiovascular diseases,
  • pregnancy,
  • history of drug abuse, and
  • history of allergy to any of the used drugs in the study

Arms & Interventions

Group KD

participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.

Intervention: Dexmedetomidine

Group KP

participants received loading of ketamine 1 mg/kg and propofol 1 mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25 µg/kg/hr dexmedetomidine throughout the procedure.

Intervention: Propofol

Outcomes

Primary Outcomes

induction time

Time Frame: after 5 minutes from the start of drug infusion till target Ramsay Sedation Score ≥ 3 is reached

Time to reach target Ramsay Sedation Score ≥ 3

Recovery time

Time Frame: after 10 minutes from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening

time from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening

Study Sites (1)

Loading locations...

Similar Trials